伴t(16;21)(p11;q22)的恶性血液病的临床和实验分析  

Clinical and laboratory investigation of hematological malignancies with t(16;21)(p11;q22) translocation

作　　者：谭丽[1] 谭获[1] 刘文丹[1] 李海明[1] 

机构地区：[1]广州医学院第一附属医院海印院区肿瘤血液中心,510230

出　　处：《检验医学与临床》2011年第20期2440-2441,共2页Laboratory Medicine and Clinic

基　　金：广州医学院博士专项基金资助项目(092402)

摘　　要：目的探讨伴t(16;21)(p11;q22)的恶性血液病的临床及实验室特征。方法骨髓细胞24 h培养后按常规方法制备染色体,用RHG显带技术进行细胞遗传学分析。结果 1例M2的患者其核型分析结果有t(16;21)(p11;q22)的异常,临床和血液学改变符合急性髓细胞白血病-M2a诊断,化疗后未获得完全缓解,中位生存期为6个月。结论 t(16;21)(p11;q22)是一类很独特的白血病亚型有关的易位,为少见的非随机的染色体易位,其临床预后差。Objective To investigate the clinical and laboratory characteristics of hematological malignancies with t（16;21）（p11;q22） translocation.Methods Bone marrow cell chromosome specimens were carried out by short-term culture,and chromosome karyotype analysis was made by RHG banding technique.Results The chromosome karyotype analysis of one leukemia patient had t（16;21）（p11;q22） translocation.The leukemia type of this patient was AML-M2a which was identified by clinic and hematological observation.This patient did not obtain complete remission after chemotherapy and the median survival time was 6 months.Conclusion t（16;21）（p11;q22） translocation is a rare and recurring chromosome abnormality,which is related to a specific type of AML.The prognosis of the AML patients with this chromosome abnormality is poor.

关 键 词：染色体 易位 细胞遗传学 急性白血病 

分 类 号：R733[医药卫生—肿瘤]